Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions reflect a consensus on the critical importance of the study, with users highlighting its relevance to treatment outcomes and future research. The tone, emphasizing phrases like 'significantly worse survival' and 'urgent need for tailored therapies,' exemplifies a strong recognition of the study’s significance and practical implications in the field of multiple myeloma research.
Most discussions strongly support the findings of the publication, emphasizing that having two or more high-risk chromosomal abnormalities in multiple myeloma leads to worse survival outcomes.
Posts demonstrate high curiosity, referencing the clinical significance and the need for tailored therapies, indicating that the research resonates with ongoing medical debates.
Many responses entail detailed comments, quotes, and references to related discussions or podcasts, showing deep engagement with the study's implications.
The discourse underscores the publication’s high perceived impact, highlighting its importance for treatment strategies and the urgent need for targeted interventions.
Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associated with highest unmet need in NDMM and RRMM, across time and treatment modalities. https://t.co/SLXKqCTfdo
Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bmtsm @MyMKaiser @JCO_ASCO https://t.co/qIqZhwgzhV
Presence of ≥2 high-risk chromosomal abnormalities is associated with the poorest outcome in NDMM and RRMM, and across treatment modalities #mmsm #bmtsm @JCO_ASCO @MyMKaiser https://t.co/dFcdjw3Dd2
#Paper | Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory #MultipleMyeloma @ASCO @JCO_ASCO Access the entire article here
To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: https://t.co/a4VBqrRETb @columbiacancer
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: https://t.co/x248hNXsQk. #mmsm
This episode summarizes the study on how high-risk cytogenetic abnormalities affect survival in newly diagnosed and relapsed-refractory multiple myeloma, highlighting the importance of tailored treatment strategies for…
This episode summarizes the International Myeloma Society and International Myeloma Working Group consensus on high-risk multiple myeloma, including recent research on how co-occurring high-risk cytogenetic…
Having 2 or more high-risk cytogenetic abnormalities - t(4;14), t(14;16), del(17p), and gain(1q) - in multiple myeloma is worse than having 1 or no high-risk cytogenetic abnormality https://t.co/lhtMQRBC4C https://t.co/P1KJACCxaS
High-risk cytogenetic abnormalities in multiple myeloma drastically worsen progression-free and overall survival, signaling urgent need for tailored therapies. by Kaiser MF, Sonneveld P (...) Weinhold N et 26 al. in J Clin Oncol https://t.co/YPJ7phKFrJ #MedX #MedResearch
RT @Transplant_Doc: Presence of ≥2 high-risk chromosomal abnormalities is associated with the poorest outcome in NDMM and RRMM, and across…
RT @Transplant_Doc: Presence of ≥2 high-risk chromosomal abnormalities is associated with the poorest outcome in NDMM and RRMM, and across…
RT @Transplant_Doc: Presence of ≥2 high-risk chromosomal abnormalities is associated with the poorest outcome in NDMM and RRMM, and across…
Presence of ≥2 high-risk chromosomal abnormalities is associated with the poorest outcome in NDMM and RRMM, and across treatment modalities #mmsm #bmtsm @JCO_ASCO @MyMKaiser https://t.co/dFcdjw3Dd2
RT @MSHughes_MD: To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: ht…
RT @MSHughes_MD: To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: ht…
RT @MSHughes_MD: To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: ht…
To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: https://t.co/a4VBqrRETb @columbiacancer
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
RT @MyMKaiser: Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associa…
Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associated with highest unmet need in NDMM and RRMM, across time and treatment modalities. https://t.co/SLXKqCTfdo
RT @FundacionECO: #Paper | Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory #Mul…
#Paper | Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory #MultipleMyeloma @ASCO @JCO_ASCO Access the entire article here
Patients with two or more high-risk cytogenetic abnormalities have significantly worse survival outcomes in multiple myeloma, highlighting urgent treatment needs. by Kaiser MF, Sonneveld P (...) Weinhold N et 26 al. in J Clin Oncol https://t.co/YPJ7phKFrJ #MedX #MedResearch
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: https://t.co/x248hNXsQk. #mmsm
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
RT @Transplant_Doc: Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bm…
Occurrence of ≥two HRCAs is associated with the poorest outcome in NDMM and RRMM, across treatment modalities #mmsm #bmtsm @MyMKaiser @JCO_ASCO https://t.co/qIqZhwgzhV
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma | Journal of Clinical Oncology @JCO_ASCO https://t.co/XTUPMBtQQ6